Fundraising Fox
Tune Therapeutics
Durham and Seattle, US · Founded 2020 · Delaware corporation · 64 employees on LinkedIn · 10 known investors
Find your way into Tune Therapeutics
Sign up to see every warm intro you have to Tune Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tune Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
Founders & leadership
Tune Therapeutics was founded in 2020 by Akira Matsuno, Derek Jantz, and Charles Gersbach.
Board
Investors · 10
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · fiercebiotech.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: RV Invest GmbH's portfolio page · Not right? Tell us
How we know: Saisei Ventures's portfolio page · Not right? Tell us
How we know: fiercebiotech.com · Not right? Tell us
How we know: funding news · fiercebiotech.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$357.4M disclosed across 2 rounds · 2023–2025
- $175MSeries BJan 2025 · 3 sources
Hevolution Foundation (lead), New Enterprise Associates (lead), Regeneron Ventures (lead), Yosemite (lead)
Source ↗
▶$182.4MraisedJan 2025 · 39 investors · BiotechnologyRule 506(b)
- Dan McHughExecutive Officer, Director
- Akira MatsunoExecutive Officer
- Blythe SatherExecutive Officer
- Derek JantzExecutive Officer
- Charles GersbachDirector
- John McHutchisonDirector
- Yuan ZhangExecutive Officer
- Zachary HaleExecutive Officer
- Ali BehbahaniDirector
- Offering amount
- $208M
- Amount sold
- $182.4M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Tune Therapeutics went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Tune Therapeutics.
In the news
Frequently asked questions
- What does Tune Therapeutics do?
- Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
- Who founded Tune Therapeutics?
- Tune Therapeutics was founded by Akira Matsuno, Derek Jantz, Charles Gersbach in 2020.
- Who are Tune Therapeutics's investors?
- Tune Therapeutics's investors include Duke Capital Partners, Hatteras Venture Partners, Mission Biocapital, New Enterprise Associates (NEA), Pappas Capital, RV Invest GmbH, Saisei Ventures, Regeneron Ventures and 1 more.
- How much funding has Tune Therapeutics raised?
- Tune Therapeutics has disclosed $357.4M raised across 2 rounds.
- Where is Tune Therapeutics headquartered?
- Tune Therapeutics is headquartered in Durham and Seattle, US.